Abiomed hits enrollment goal in Recover Right trial

Abiomed says it hit the 30-patient mark in the Recover Right study of its Impella RP heart pump.

Abiomed (NSDQ:ABMD) said it plans to ask the FDA to allow more patients to enroll in the Recover Right trial of its Impella RP right-side heart pump, now that it's met the 30-patient goal for the study.

Food & Drug Administration (FDA), Abiomed Inc.

News Well, Clinical Trials, Cardiac Assist Devices

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1fKcYGu